Öz
Paget hastalığı PH çoğunlukla yaşlı popülasyonu etkileyen ,kemik döngüsünde fokal artışla karakterize bir hastalıktır. Osteoporozdan sonra ikinci sıklıkla görülen metabolik kemik hastalığıdır. PH tanısı en sık başka hastalıkların incelemeleri sırasında tesadüfi olarak konur. Tutulan kemiklerde ağrı PH’nın en sık görülen semptomudur. Tedavide bifosfonatlar ilk seçenek ilaçlardır. Biz, daha önceden lomber Herni Nukleus Pulposus HNP tanısı ile takip edilen ve kliniğimizce PH tanısı konulan bir olguyu sunduk
Anahtar Kelimeler
Kaynakça
- Walsh JP. Paget’s disease of bone. Med J Aust 2004;181:262-5.
- The Journal of Clinical Investigation Volume 115 Number 2 February 2005 of bone. Arq Bras Endocrinol Metab 2006;50:814-22.
- Langston AL, Ralston SH. Management of Paget's disease of bone.Rheumatology 2004;43(8):955-9.
- Siris ES, Roodman GD. In: Favus MJ, ed. Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism. 6th ed. Washington, DC: ASBMR; 2006:320-330
- Seton M, Choi HK, Hansen MF, et al. Analysis of environmental factors infamilial versus sporadic Paget’s disease of bone — the New EnglandRegistry for Paget’s Disease of Bone. J Bone Miner Res 2003; 18: 1519-1524.
- Hocking LJ, Lucas GJA, Daroszewska A, et al. UBA domain mutations of SQSTM1 in Paget’s disease of bone: genotype phenotype correlation, functional analysis and structural consequences. J Bone Miner Res 2004; 19: 1122-1127.
- Kelepourus N. Clinical manifastations&Diagnosis of paget’s disease of bone.Uptodate,2004
- Griz L, Caldas G, Banderia C, Assunçao V, Banderia F. Paget's disease of bone. Arq Bras Endocrinol Metab 2006;50:814-22.
Öz
Paget’s disease of bone PD is characterized by focal increases in bone turnover that affects mainly elderly population. PD is the second most common metabolic bone disease after osteoporosis. The diagnosis of PD is made most commonly, incidentally in patients investigations for other conditions. Pain in the involved bone s is the most common symptom of PD. Bisphosphonates are first line drugs in treatment of PD. We report a patient who was previously followed with lomber Herni Nukleus Pulposus HNP and diagnosed as PD in our clinic
Anahtar Kelimeler
Kaynakça
- Walsh JP. Paget’s disease of bone. Med J Aust 2004;181:262-5.
- The Journal of Clinical Investigation Volume 115 Number 2 February 2005 of bone. Arq Bras Endocrinol Metab 2006;50:814-22.
- Langston AL, Ralston SH. Management of Paget's disease of bone.Rheumatology 2004;43(8):955-9.
- Siris ES, Roodman GD. In: Favus MJ, ed. Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism. 6th ed. Washington, DC: ASBMR; 2006:320-330
- Seton M, Choi HK, Hansen MF, et al. Analysis of environmental factors infamilial versus sporadic Paget’s disease of bone — the New EnglandRegistry for Paget’s Disease of Bone. J Bone Miner Res 2003; 18: 1519-1524.
- Hocking LJ, Lucas GJA, Daroszewska A, et al. UBA domain mutations of SQSTM1 in Paget’s disease of bone: genotype phenotype correlation, functional analysis and structural consequences. J Bone Miner Res 2004; 19: 1122-1127.
- Kelepourus N. Clinical manifastations&Diagnosis of paget’s disease of bone.Uptodate,2004
- Griz L, Caldas G, Banderia C, Assunçao V, Banderia F. Paget's disease of bone. Arq Bras Endocrinol Metab 2006;50:814-22.
Ayrıntılar
| Birincil Dil | Türkçe |
|---|---|
| Bölüm | Research Article |
| Yazarlar | |
| Yayımlanma Tarihi | 1 Mart 2009 |
| Yayımlandığı Sayı | Yıl 2009 Cilt: 15 Sayı: 1 |